摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(5R,7S,8R,8aR)-5-dodecyl-7,8-epoxyoxazolidino[3,4-a]piperidine-3-one | 652539-04-3

中文名称
——
中文别名
——
英文名称
(5R,7S,8R,8aR)-5-dodecyl-7,8-epoxyoxazolidino[3,4-a]piperidine-3-one
英文别名
(1S,2R,4S,6S)-6-dodecyl-3,9-dioxa-7-azatricyclo[5.3.0.02,4]decan-8-one
(5R,7S,8R,8aR)-5-dodecyl-7,8-epoxyoxazolidino[3,4-a]piperidine-3-one化学式
CAS
652539-04-3
化学式
C19H33NO3
mdl
——
分子量
323.476
InChiKey
KDKDFFRDYIRFNG-XLAORIBOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6
  • 重原子数:
    23
  • 可旋转键数:
    11
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.95
  • 拓扑面积:
    42.1
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (5R,7S,8R,8aR)-5-dodecyl-7,8-epoxyoxazolidino[3,4-a]piperidine-3-one三乙基硼氢化锂 作用下, 以 四氢呋喃 为溶剂, 反应 2.0h, 以98%的产率得到(5R,8R,8aR)-5-dodecyl-8-hydroxyoxazolidino[3,4-a]piperidine-3-one
    参考文献:
    名称:
    通过手性亚胺的烯丙基化和闭环复分解反应制备手性反式-6-烷基-2-羟甲基-1,2,5,6-四氢吡啶的新途径-(-)-3-epi-Deoxoprosopinine的全合成
    摘要:
    报道了一种从 Garner 醛中分五个步骤制备对映体纯反式-6-烷基-2-羟甲基-1,2,5,6-四氢吡啶的新途径,总产率高于 35%。该策略基于原位形成的手性亚氨基醇的烯丙基化,然后是闭环复分解。这种新方法用于 (-)-3-epi-deoxoprosopinine 的首次全合成。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003)
    DOI:
    10.1002/ejoc.200300423
  • 作为产物:
    参考文献:
    名称:
    通过手性亚胺的烯丙基化和闭环复分解反应制备手性反式-6-烷基-2-羟甲基-1,2,5,6-四氢吡啶的新途径-(-)-3-epi-Deoxoprosopinine的全合成
    摘要:
    报道了一种从 Garner 醛中分五个步骤制备对映体纯反式-6-烷基-2-羟甲基-1,2,5,6-四氢吡啶的新途径,总产率高于 35%。该策略基于原位形成的手性亚氨基醇的烯丙基化,然后是闭环复分解。这种新方法用于 (-)-3-epi-deoxoprosopinine 的首次全合成。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003)
    DOI:
    10.1002/ejoc.200300423
点击查看最新优质反应信息

文献信息

  • A Novel Route to Chiraltrans-6-Alkyl-2-hydroxymethyl-1,2,5,6-tetrahydropyridines by Allylation of Chiral Imines and Ring-Closing Metathesis− Total Synthesis of (−)-3-epi-Deoxoprosopinine
    作者:François-Xavier Felpin、Kamal Boubekeur、Jacques Lebreton
    DOI:10.1002/ejoc.200300423
    日期:2003.12
    A novel route to enantiomerically pure trans-6-alkyl-2-hydroxymethyl-1,2,5,6-tetrahydropyridines is reported in five steps from Garner’s aldehyde with overall yields higher than 35 %. This strategy is based on the allylation of chiral imino alcohols formed in situ followed by a ring-closing metathesis. This new method was used for the first total synthesis of ()-3-epi-deoxoprosopinine. (© Wiley-VCH
    报道了一种从 Garner 醛中分五个步骤制备对映体纯反式-6-烷基-2-羟甲基-1,2,5,6-四氢吡啶的新途径,总产率高于 35%。该策略基于原位形成的手性亚氨基醇的烯丙基化,然后是闭环复分解。这种新方法用于 (-)-3-epi-deoxoprosopinine 的首次全合成。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003)
查看更多

同类化合物

7-亚乙基-环戊二烯并(b)环氧乙烷并(c)吡啶六氢衍生物. 4-甲基-3-氧杂-6-氮杂三环[3.2.0.02,4]庚烷-7-酮 3-氧杂-6-氮杂三环[3.2.2.02,4]壬烷(8CI,9CI) 3-氧杂-1-氮杂三环[5.2.0.02,4]壬烷 2-氧杂-6-氮杂三环[4.3.1.01,3]癸烷 (1S,2R,4S,5R)-3-氧杂-6-氮杂三环[3.2.1.02,4]辛烷-7-酮 (5R,7S,8R,8aR)-5-dodecyl-7,8-epoxyoxazolidino[3,4-a]piperidine-3-one (2S,2R,4S,5R,6S)-(+)-2-{2-[2-[1,3]-dioxolan-2-yl-ethyl]-6-methyl-4,5-epoxy-3,6-dihydro-2H-pyridin-1-yl}-2-phenylethanol (5R,7R,8S,8aR)-5-ethyl-7,8-epoxyoxazolidino[3,4-a]piperidine-3-one dihydroabikoviromycin (1R,6R)-1-(hydroxymethyl)-3-[(1S)-1-phenylethyl]-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1S,6S)-1-(hydroxymethyl)-3-[(1S)-1-phenylethyl]-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1aR,6aS,7R,7aS)-7-(t-butyldimethylsilyloxy)tetrahydro-1aH-oxazolo[3,4-a]oxireno[2,3-d]pyridin-4(2H)-one 11-formyl-(1rN,2tH,4tH,6cN,7tH,9tH)-3,8-dioxa-11-aza-tetracyclo[4.4.1.02,4.07,9]undecane 7-Oxa-2-azabicyclo[4.1.0]heptane (1S,6S)-1-(hydroxymethyl)-3-[(1R)-2-hydroxy-1-phenylethyl]-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1R,6R)-1-(hydroxymethyl)-3-[(1R)-2-hydroxy-1-phenylethyl]-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1R,6R)-3-[(1R)-2-[tert-butyl(dimethyl)silyl]oxy-1-phenylethyl]-1-(hydroxymethyl)-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1S,6S)-3-[(1R)-2-[tert-butyl(dimethyl)silyl]oxy-1-phenylethyl]-1-(hydroxymethyl)-7-oxa-3-azabicyclo[4.1.0]heptan-2-one 3-Oxa-10-azatricyclo[4.3.1.0~2,4~]decane (3S,5R,6R,7R)-6-hydroxy-4,9-dioxa-1-azatricyclo[5.3.0.03,5]decan-10-one (1RS,2SR,4RS,5SR)-3-oxa-6-azatricyclo[3.2.1.02,4]octan-7-one (1S,6S)-1-[[tert-butyl(dimethyl)silyl]oxymethyl]-3-[(1S)-1-phenylethyl]-7-oxa-3-azabicyclo[4.1.0]heptan-2-one 3-(methanesulfonyl)-7-oxa-3-azabicyclo[4.1.0]heptane 3α,4α-epoxy-2-piperidone (+)-tedanalactam 5-amino-1,2-anhydro-5-deoxy-D-lyxono-1,4-lactame (1R,5S,6S)-5-((tert-butyldimethylsilyl)oxy)-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1R,5R,6S)-5-((tert-butyldimethylsilyl)oxy)-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1S,6R)-4,4,6-trimethyl-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1R,6S)-4,4,6-trimethyl-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1R,6R)-3-(cyclopropylmethyl)-7-oxa-3-azabicyclo[4.1.0]heptane (1R,6R)-3-ethyl-7-oxa-3-azabicyclo[4.1.0]heptane (1R,6R)-3-(2-methylpropyl)-7-oxa-3-azabicyclo[4.1.0]heptane (1R,6R)-3-(2-methoxyethyl)-7-oxa-3-azabicyclo[4.1.0]heptane (1R,6R)-3-methyl-7-oxa-3-azabicyclo[4.1.0]heptane (1S,6S)-7-oxa-3-azabicyclo[4.1.0]heptane (1R,6S)-7-oxa-2-azabicyclo[4.1.0]heptane (1S,6R)-7-oxa-2-azabicyclo[4.1.0]heptane (1R,6R)-7-oxa-3-azabicyclo[4.1.0]heptane (1S,2S,4R,5S)-4-methyl-3-oxa-6-azatricyclo[3.2.0.02,4]heptan-7-one (2R,4S,7S)-3-oxa-1-azatricyclo[5.2.0.02,4]nonane (1S,2S,4S,5R)-4-methyl-3-oxa-6-azatricyclo[3.2.0.02,4]heptan-7-one (1S,2S,4S,5S)-4-methyl-3-oxa-6-azatricyclo[3.2.0.02,4]heptan-7-one (2S,4R,7S)-3-oxa-1-azatricyclo[5.2.0.02,4]nonane (1R,6R)-1-methyl-3-propyl-7-oxa-3-azabicyclo[4.1.0]heptane (1S,2R,4S,5S)-2-methyl-3-oxa-6-azatricyclo[3.2.0.02,4]heptan-7-one (1R,2S,4S,5S)-2-methyl-3-oxa-6-azatricyclo[3.2.0.02,4]heptan-7-one (1S,2S,4S,5S)-2-methyl-3-oxa-6-azatricyclo[3.2.0.02,4]heptan-7-one (1R,6S)-3-methyl-7-oxa-3-azabicyclo[4.1.0]heptane